I ANCHOR studiet blev behandlingseffekten af ranibizumab overfor verteporfin PDT hovedsagelig bevaret for de 3 VFQ- 25 opnåelser efter 24 måneder.
In the ANCHOR study, the treatment effect of ranibizumab over verteporfin PDT was essentially maintained for the three VFQ-25 scores after 24 months.